Parnell Pharmaceuticals Holdings Return on Tangible Equity 2014-2018 | PARNF
Current and historical return on tangible equity values for Parnell Pharmaceuticals Holdings (PARNF) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Parnell Pharmaceuticals Holdings Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2018-03-31 |
$-0.01B |
$-0.02B |
56.00% |
| 2016-12-31 |
$-0.02B |
$-0.01B |
666.67% |
| 2016-09-30 |
$-0.02B |
$0.00B |
-500.00% |
| 2015-12-31 |
$-0.01B |
$0.00B |
-250.00% |
| 2015-09-30 |
$0.00B |
|
-51.61% |
| 2015-06-30 |
$0.00B |
$0.01B |
-38.71% |
| 2014-12-31 |
$-0.01B |
$0.02B |
-75.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
Parnell Pharmaceuticals Holdings Ltd. is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing animal health solutions. It manufactures and markets cattle reproduction, cattle mastitis, anesthetics, laminitis treatment, and orthopedic treatment products. The Company operates in four segments: Companion Animal, Production Animal-Unites States, and Production Animal-rest of the world and Manufacturing Operations. ZYDAX (R), GLYDE (R) and TERGIVE (R) are Parnell's premium osteoarthritis product suite. Parnell Pharmaceuticals Holdings Ltd. is headquartered in Alexandria, Australia.
|
